Pharmacotherapy for Diabetes and Lipid Disorders PDF 2024/2025
Document Details
Uploaded by LaudableCornflower3917
Collegium Medicum Uniwersytetu Mikołaja Kopernika
2024
Rafał Porzych
Tags
Summary
This document, a presentation from 2024/2025 by Rafał Porzych, focuses on pharmacotherapy for treating both diabetes and lipid disorders. It covers the details of lipoproteins including drugs such as statins and fibrates. Non-pharmacological treatments, and the diagnosis of carbonate metabolism along with antidiabetic drugs are also discussed.
Full Transcript
Pharmacotherapy for diabetes and lipid disorders 2024/2025 Rafał Porzych Pharmacotherapy for lipid disorders Lipoproteins Major lipoproteins in blood: - high-density lipoproteins (HDL) - low-dens...
Pharmacotherapy for diabetes and lipid disorders 2024/2025 Rafał Porzych Pharmacotherapy for lipid disorders Lipoproteins Major lipoproteins in blood: - high-density lipoproteins (HDL) - low-density lipoproteins (LDL) - intermediate-density lipoproteins (IDL) - very-low-density lipoproteins (VLDL) - chylomicrons (ultra low-density lipoproteins; ULDL) and lipoprotein(a). Lipid disorders Dyslipidemia is a condition in which the concentrations of lipids and lipoproteins in plasma do not correspond to the values considered desirable. In clinical practice, the following are distinguished: hypercholesterolemia, atherogenic dyslipidemia (including mixed hyperlipidemia), hypertriglyceridemia and increased lipoprotein(a) concentration. Lipid metabolism disorders are the most common risk factor for cardiovascular diseases in Poland. The incidence of dyslipidemia in Poland is estimated at 60-80% of people in the population over 18 years of age. Current lipid profile reference values Total cholesterol:
